Hi Catherine, You will find that a major active ingredient of Noni, barley, oats, mushroom, Aloe, wheat grass, yeast and more, is the polysaccharide 1,3Beta Glucan.
There has been many studies done on this substance, but because of its very high price (until recently) it is not widely known. Ivan. > -----Original Message----- > From: Catherine Creel [mailto:ccr...@maine.rr.com] > Sent: Thursday, 28 March 2002 2:42 p.m. > To: silver-list@eskimo.com > Subject: Re: CS>Tahitain Noni > > > <<Gladys it all depends on what you were taking the Noni > Juice for. One > bottle will not tell you a thing>> > > we are a society that is promised "magic pills" by > conventional medicine, > and although nthey don't deliver, we have been indoctrinated > into thinking > this way so still look fro the "magic pill" in everything we try. > > The benefits of Noni are well-documented. Below are two of nineteen > studies found at PubMed on Noni--Catherine > > > Ann N Y Acad Sci 2001 Dec;952:161-8 > > Cancer preventive effect of Morinda citrifolia (Noni). > > Wang MY, Su C. > > Department of Pathology, UIC College of Medicine, Rockford, > Illinois 61107, > USA. mianw...@uic.edu > > Morinda citrifolia (Noni) has been extensively used in folk > medicine by > Polynesians for over 2,000 years. It has been reported to have broad > therapeutic effects, including anticancer activity, in both clinical > practice and laboratory animal models. The mechanism for these effects > remains unknown. The hypothesis that Morinda citrifolia > possesses a cancer > preventive effect at the initiation stage of carcinogenesis > was studied. Our > preliminary data indicated that 10% Tahitian Noni Liquid > Dietary Supplement > or Tahitian Noni Juice (TNJ), made from Morinda citrifolia > fruit by Morinda > Inc, in drinking water for one week was able to prevent > DMBA-DNA adduct > formation. The levels of DMBA-DNA adducts were reduced by 30% > in the heart, > 41% in the lung, 42% in the liver, and 80% in the kidney of > female SD rats. > Even more dramatic results were obtained in male C57 BL-6 > mice: 10% TNJ was > able to reduce DMBA-DNA adduct formation by 60% in the heart, > 50% in the > lung, 70% in the liver, and 90% in the kidney. In order to explore the > mechanism of this preventive effect, the antioxidant activity > of TNJ was > examined in vitro by lipid hydroperoxide (LPO) and > tetrazolium nitroblue > (TNB) assays. In the LPO assay, LPO oxidizes leucomethylene blue to > methylene blue in the presence of hemoglobin. The resultant > blue color was > quantified at 660 nm spectrophotometrically. In the TNB > assay, superoxide > anion radicals (SAR) reduce TNB into formazan blue that was > also measured by > absorption at 602 nm. TNJ showed a dose-dependent inhibition > of both LPO and > SAR in our system. The antioxidant activity of TNJ was compared to the > effects of vitamin C, grape seed powder (GSP), and pycnogenol > (PYC) at the > daily dose per serving level recommended by U.S.RDAs or > manufacturers. The > results suggest that prevention of carcinogen-DNA adduct > formation and the > antioxidant activity of TNJ may contribute to the cancer > preventive effect > of Morinda citrifolia. > > PMID: 11795436 > ________________________________________________________ > > Phytother Res 1999 Aug;13(5):380-7 > > > An immunomodulatory polysaccharide-rich substance from the > fruit juice of > Morinda citrifolia (noni) with antitumour activity. > > Hirazumi A, Furusawa E. > > Department of Pharmacology, John A., Burns School of > Medicine, 1960 East > West Road, University of Hawaii, Honolulu, HI 96822, USA. > > The fruit juice of Morinda citrifolia (noni) contains a > polysaccharide-rich > substance (noni-ppt) with antitumour activity in the Lewis lung (LLC) > peritoneal carcinomatosis model. Therapeutic administration > of noni-ppt > significantly enhanced the duration of survival of inbred > syngeneic LLC > tumour bearing mice. It did not exert significant cytotoxic > effects in an > adapted culture of LLC cells, LLC1, but could activate > peritoneal exudate > cells (PEC) to impart profound toxicity when co-cultured with > the tumour > cells. This suggested the possibility that noni-ppt may > suppress tumour > growth through activation of the host immune system. > Concomitant treatment > with the immunosuppressive agent, 2-chloroadenosine (C1-Ade) > or cyclosporin > (cys-A) diminished its activity, thereby substantiating an > immunomodulatory > mechanism. Noni-ppt was also capable of stimulating the > release of several > mediators from murine effector cells, including tumour > necrosis factor-alpha > (TNF-alpha), interleukin-1beta (IL-1beta), IL-10, IL-12 p70, > interferon-gamma (IFN-gamma) and nitric oxide (NO), but had > no effect on > IL-2 and suppressed IL-4 release. Improved survival time and curative > effects occurred when noni-ppt was combined with sub-optimal > doses of the > standard chemotherapeutic agents, adriamycin (Adria), > cisplatin (CDDP), > 5-fluorouracil (5-FU), and vincristine (VCR), suggesting > important clinical > applications of noni-ppt as a supplemental agent in cancer treatment. > Copyright 1999 John Wiley & Sons, Ltd. > > PMID: 10441776 -- The silver-list is a moderated forum for discussion of colloidal silver. To join or quit silver-list or silver-digest send an e-mail message to: silver-list-requ...@eskimo.com -or- silver-digest-requ...@eskimo.com with the word subscribe or unsubscribe in the SUBJECT line. To post, address your message to: silver-list@eskimo.com Silver-list archive: http://escribe.com/health/thesilverlist/index.html List maintainer: Mike Devour <mdev...@eskimo.com>
